+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Retinal Disorder Treatment Market by Disease (Age-Related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion), Drug Class (Anti-VEGF, Corticosteroids), Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Retinal Disorder Treatment Market by Disease (Age-Related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion), Drug Class (Anti-VEGF, Corticosteroids), Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Retinal Disorder Treatment Market by Disease (Age-Related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion), Drug Class (Anti-VEGF, Corticosteroids), Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 189 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6012391
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The retinal disorder treatment market is rapidly evolving amidst technological innovation and rising global demand, driving the need for strategic foresight among industry leaders. As clinical practices and reimbursement models shift, senior decision-makers require clear insights to navigate emerging opportunities and challenges in this complex therapeutic space.

Market Snapshot: Retinal Disorder Treatment Market Overview

The Retinal Disorder Treatment Market grew from USD 9.38 billion in 2024 to USD 10.27 billion in 2025. It is expected to continue growing at a CAGR of 8.97%, reaching USD 15.72 billion by 2030. This growth reflects increased disease prevalence, an expanding aging population, and escalating demand for advanced therapies. Senior decision-makers are recognizing the strategic significance of this market as innovation accelerates and global health needs shift.

Scope & Segmentation of the Retinal Disorder Treatment Market

This report offers comprehensive coverage and segmentation, enabling targeted strategies for stakeholders. Key areas analyzed include:

  • Disease Subtypes: Age-related macular degeneration (dry and wet forms), diabetic retinopathy (nonproliferative and proliferative), retinal vein occlusion (branch and central variants).
  • Drug Class: Anti-VEGF agents (aflibercept, bevacizumab, brolucizumab, ranibizumab) and corticosteroids (dexamethasone implant, fluocinolone acetonide, triamcinolone acetonide).
  • Route of Administration: Intravitreal injection, oral, subretinal, and topical delivery methods.
  • End User Categories: Ambulatory surgical centers, multispecialty clinics, ophthalmology clinics, home healthcare, inpatient hospitals, and outpatient hospitals.
  • Distribution Channels: Hospital pharmacy, online pharmacy, retail pharmacy.
  • Key Regions: Americas (with focus on markets in the United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (UK, Germany, France, UAE, South Africa, more), Asia-Pacific (China, India, Japan, Australia, and others).
  • Technology & Innovation: Next-generation imaging modalities, gene therapy vectors, AI-powered diagnostic tools, sustained-release drug delivery systems, and real-time monitoring devices.
  • Notable Companies: Regeneron Pharmaceuticals, Novartis AG, F. Hoffmann-La Roche Ltd, Bayer AG, AbbVie Inc., Santen Pharmaceutical Co., Ltd., Bausch Health, Alimera Sciences, Carl Zeiss Meditec, NIDEK Co., Ltd.

Key Takeaways: Strategic Insights for Senior Decision-Makers

  • The move toward precision medicine and personalized treatment is reshaping clinical standards, bringing tailored interventions for better patient outcomes.
  • Technological advancements, especially AI and advanced imaging, are enabling earlier detection and improved monitoring of retinal disorders.
  • Patient-centric care models with real-time monitoring and adaptive dosing are gaining traction, influencing both adherence and outcomes.
  • Collaborations, including academic-private partnerships, are expediting the development of new therapies and streamlining regulatory processes.
  • Supply chain resilience is being prioritized as manufacturers respond to external pressures, optimizing sourcing and inventory strategies to ensure product availability.
  • Regional differences in healthcare policy, infrastructure, and adoption rates require nuanced go-to-market strategies aligned with local needs and resources.

Tariff Impact: Navigating Policy Dynamics

United States tariff adjustments on pharmaceutical ingredients and ophthalmic devices have affected costs and manufacturing logistics for the retinal disorder treatment market. Suppliers are adopting diversification and advanced inventory solutions to adapt to these shifts. These efforts help maintain stability for stakeholders and support continued patient access to essential therapies, despite evolving trade policy landscapes.

Methodology & Data Sources

This report integrates primary research from industry experts, clinicians, and KOLs, paired with thorough secondary analysis of regulatory filings, scientific publications, and patent literature. Data is cross-validated with independent databases, and quality assurance protocols ensure the integrity and reliability of all market insights presented.

Why This Report Matters

  • It delivers actionable segmentation and regional intelligence, empowering decision-makers to prioritize investments and strategic initiatives.
  • It equips leaders to anticipate the effects of regulatory and policy trends on supply chains and market dynamics for retinal disorder treatments.
  • The report distills emerging innovation and collaboration trends to inform both competitive and partnership strategies for long-term growth.

Conclusion

The retinal disorder treatment market continues to evolve, shaped by innovation, policy, and collaborative networks. A data-driven and regionally aligned strategy will be essential for stakeholders aiming to capture new opportunities and deliver patient-centered solutions in this dynamic sector.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emergence of gene therapy pipelines targeting inherited retinal diseases for long-term vision restoration
5.2. Expansion of anti-VEGF biosimilars reducing treatment costs and improving accessibility in AMD and DME
5.3. Advancements in sustained-release intravitreal implants extending dosing intervals and patient compliance
5.4. Development of retinal prostheses integrating AI-driven vision processing to enhance low-light perception
5.5. Growth of home-based OCT monitoring platforms enabling early detection and management of retinal disease
5.6. Rise of complement inhibition therapies addressing geographic atrophy progression in age-related macular degeneration
5.7. Integration of teleophthalmology services improving access to retinal screening in rural and underserved populations
5.8. Innovations in CRISPR-based gene editing for targeted correction of polymorphisms in retinal dystrophies
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Retinal Disorder Treatment Market, by Disease
8.1. Introduction
8.2. Age-Related Macular Degeneration
8.2.1. Dry Age-Related Macular Degeneration
8.2.2. Wet Age-Related Macular Degeneration
8.3. Diabetic Retinopathy
8.3.1. Nonproliferative
8.3.2. Proliferative
8.4. Retinal Vein Occlusion
8.4.1. Branch Vein Occlusion
8.4.2. Central Vein Occlusion
9. Retinal Disorder Treatment Market, by Drug Class
9.1. Introduction
9.2. Anti-VEGF
9.2.1. Aflibercept
9.2.2. Bevacizumab
9.2.3. Brolucizumab
9.2.4. Ranibizumab
9.3. Corticosteroids
9.3.1. Dexamethasone Implant
9.3.2. Fluocinolone Acetonide
9.3.3. Triamcinolone Acetonide
10. Retinal Disorder Treatment Market, by Route Of Administration
10.1. Introduction
10.2. Intravitreal Injection
10.3. Oral
10.4. Subretinal
10.5. Topical
11. Retinal Disorder Treatment Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Clinics
11.3.1. Multispecialty Clinics
11.3.2. Ophthalmology Clinics
11.4. Home Healthcare
11.5. Hospitals
11.5.1. Inpatient
11.5.2. Outpatient
12. Retinal Disorder Treatment Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Americas Retinal Disorder Treatment Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Retinal Disorder Treatment Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Retinal Disorder Treatment Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Regeneron Pharmaceuticals, Inc.
16.3.2. Novartis AG
16.3.3. F. Hoffmann-La Roche Ltd
16.3.4. Bayer AG
16.3.5. AbbVie Inc.
16.3.6. Santen Pharmaceutical Co., Ltd.
16.3.7. Bausch Health Companies Inc.
16.3.8. Alimera Sciences, Inc.
16.3.9. Carl Zeiss Meditec AG
16.3.10. NIDEK Co., Ltd.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. RETINAL DISORDER TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. RETINAL DISORDER TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. RETINAL DISORDER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. RETINAL DISORDER TREATMENT MARKET: RESEARCHAI
FIGURE 26. RETINAL DISORDER TREATMENT MARKET: RESEARCHSTATISTICS
FIGURE 27. RETINAL DISORDER TREATMENT MARKET: RESEARCHCONTACTS
FIGURE 28. RETINAL DISORDER TREATMENT MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. RETINAL DISORDER TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DRY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DRY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY NONPROLIFERATIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY NONPROLIFERATIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY PROLIFERATIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY PROLIFERATIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY BRANCH VEIN OCCLUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY BRANCH VEIN OCCLUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY CENTRAL VEIN OCCLUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY CENTRAL VEIN OCCLUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DEXAMETHASONE IMPLANT, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DEXAMETHASONE IMPLANT, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY FLUOCINOLONE ACETONIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY FLUOCINOLONE ACETONIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY TRIAMCINOLONE ACETONIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY TRIAMCINOLONE ACETONIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY SUBRETINAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY SUBRETINAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY MULTISPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY MULTISPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY INPATIENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY INPATIENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY OUTPATIENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 151. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2018-2024 (USD MILLION)
TABLE 152. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2025-2030 (USD MILLION)
TABLE 153. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2024 (USD MILLION)
TABLE 154. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2025-2030 (USD MILLION)
TABLE 155. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2024 (USD MILLION)
TABLE 156. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2025-2030 (USD MILLION)
TABLE 157. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2024 (USD MILLION)
TABLE 158. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2025-2030 (USD MILLION)
TABLE 159. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 160. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 161. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 162. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 163. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 164. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 165. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 166. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 167. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 168. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 169. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 170. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 171. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 172. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 173. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 174. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 175. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2018-2024 (USD MILLION)
TABLE 176. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2025-2030 (USD MILLION)
TABLE 177. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2024 (USD MILLION)
TABLE 178. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2025-2030 (USD MILLION)
TABLE 179. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2024 (USD MILLION)
TABLE 180. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2025-2030 (USD MILLION)
TABLE 181. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2024 (USD MILLION)
TABLE 182. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2025-2030 (USD MILLION)
TABLE 183. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 184. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 185. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 186. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 187. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 188. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 189. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 190. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 191. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 192. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 193. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 194. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 195. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 196. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 197. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2025-2030 (USD MILLION)
TABLE 201. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2024 (USD MILLION)
TABLE 202. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2025-2030 (USD MILLION)
TABLE 203. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2024 (USD MILLION)
TABLE 204. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2025-2030 (USD MILLION)
TABLE 205. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2024 (USD MILLION)
TABLE 206. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2025-2030 (USD MILLION)
TABLE 207. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 208. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 209. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 210. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 217. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 218. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 219. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 220. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 221. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 222. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 223. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2018-2024 (USD MILLION)
TABLE 224. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2025-2030 (USD MILLION)
TABLE 225. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2024 (USD MILLION)
TABLE 226. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2025-2030 (USD MILLION)
TABLE 227. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2024 (USD MILLION)
TABLE 228. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2025-2030 (USD MILLION)
TABLE 229. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2024 (USD MILLION)
TABLE 230. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2025-2030 (USD MILLION)
TABLE 231. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 232. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 233. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 234. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 235. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 236. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 237. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 238. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 239. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 240. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 241. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 242. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 243. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 244. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 245. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2018-2024 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2025-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2024 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2025-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2024 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2025-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2024 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2025-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 273. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2018-2024 (USD MILLION)
TABLE 274. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2025-2030 (USD MILLION)
TABLE 275. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2024 (USD MILLION)
TABLE 276. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2025-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2024 (USD MILLION)
TABLE 278. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2025-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2024 (USD MILLION)
TABLE 280. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2025-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 282. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
TABLE 284. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2025-2030 (USD MILLION)
TABLE 285. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 286. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 287. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 288. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 289. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 292. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 293. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 294. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 295. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 296. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 297. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2018-2024 (USD MILLION)
TABLE 298. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2025-2030 (USD MILLION)
TABLE 299. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2024 (USD MILLION)
TABLE 300. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2025-2030 (USD MILLION)
TABLE 301. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2024 (USD MILLION)
TABLE 302. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2025-2030 (USD MILLION)
TABLE 303. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2024 (USD MILLION)
TABLE 304. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2025-2030 (USD MILLION)
TABLE 305. GERMANY RETINAL DISORDER TREATMENT MARKE

Samples

Loading
LOADING...

Companies Mentioned

  • Regeneron Pharmaceuticals, Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Bayer AG
  • AbbVie Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Bausch Health Companies Inc.
  • Alimera Sciences, Inc.
  • Carl Zeiss Meditec AG
  • NIDEK Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages189
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 10.27 Billion
Forecasted Market Value ( USD ) by 2030 $ 15.72 Billion
Compound Annual Growth Rate8.9%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Retinal Disorder Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Retinal Disorder Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 138 Pages
  • Global
From
Retinal Disorder Treatment - Global Strategic Business Report - Product Image

Retinal Disorder Treatment - Global Strategic Business Report

  • Report
  • 375 Pages
  • Global
From
Retinal Disorder Treatment Market Report 2025 - Product Image

Retinal Disorder Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Ophthalmic Disease Therapeutics Market (2024 Edition): Analysis By Indication (Age-related macular degeneration, Diabetic macular edema, Other retinal disorders), By Therapies, By Distribution Channel, By Region, By Country: Market Insights and Forecast (2020-2030) - Product Image

Ophthalmic Disease Therapeutics Market (2024 Edition): Analysis By Indication (Age-related macular degeneration, Diabetic macular edema, Other retinal disorders), By Therapies, By Distribution Channel, By Region, By Country: Market Insights and Forecast (2020-2030)

  • Report
  • 253 Pages
  • Global
From
Retinal Disease Therapy Options Market by Indication, Therapy Type, Route Of Administration, End User, Distribution Channel - Global Forecast to 2030 - Product Image

Retinal Disease Therapy Options Market by Indication, Therapy Type, Route Of Administration, End User, Distribution Channel - Global Forecast to 2030

  • Report
  • 194 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.